1258MO Low dose versus standard dose pembrolizumab for treatment of stage IV stage non-small cell lung carcinoma: Results of the pre-planned interim analysis of the NVALT-30 clinical trial
M. van den Heuvel, Vincent van der Noort, Rob ter Heine
Topics & Concepts
MedicineStage (stratigraphy)Interim analysisPembrolizumabOncologyInterimCarcinomaClinical trialInternal medicineCancerImmunotherapyHistoryPaleontologyBiologyArchaeologyCancer Immunotherapy and BiomarkersLung Cancer Diagnosis and TreatmentLung Cancer Treatments and Mutations